Novo Nordisk researchers nominated for Europe's top innovation prize

Novo NordiskA team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.

Prizes will be awarded in four categories: industry, small- and medium-sized enterprises/research institutes, non-European countries and lifetime achievement. Novo Nordisk is nominated in the 'industry' category, competing against French aviation company Airbus and German automaker Audi.

The invention for which the Novo Nordisk researchers are nominated concerns Levemir® (insulin detemir), a long-acting modern insulin that covers the body's basal insulin need and which today is used by more than one million people with diabetes. They have been nominated for "significantly improving the safety and quality of life of diabetes patients with a new insulin derivative for once-daily administration".

"The patent describes a technology for prolonging the duration of action of insulin. The invention is pioneering a new generation of modified human peptide hormones, because the technology can be applied more broadly to optimise the therapeutic value of proteins, including insulin and GLP-1," explains Svend Havelund, one of the inventors.

This year's award ceremony will be held alongside the European Patent Forum 2008, 'Inventing a cleaner future', in Ljubljana. The awards will be presented by Danilo Türk, the president of the Republic of Slovenia, and Alison Brimelow, the president for the European Patent Office.

The prize recognises inventors and innovations that have made a significant and lasting contribution to technical development in Europe and beyond and thus have strengthened Europe's economic position. All the nominated projects were patented by the European Patent Office between 1993 and 2002.

The team of Novo Nordisk researchers are Svend Havelund, John Broberg Halstrom, Ib Jonassen, Asser Sloth Andersen and Jan Markussen.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...